Answers are grounded in this paper and cite their sources.
Background Depressive symptoms are common in patients with cancer, but their associations with survival and treatment response in triple-negative breast cancer (TNBC) remain uncertain. Methods This single-center retrospective study screened 19,335 patients with breast cancer treated during 2015–2025 and included 4,060 patients with TNBC. A single baseline Patient Health Questionnaire-9 (PHQ-9) assessment classified patients into normal/mild (score <10; n = 3,666) and moderate/severe (score ≥10; n = 394) symptom groups. Survival analyses included 3,878 patients without baseline distant metastasis; pathological complete response (pCR) analyses included 1,689 neoadjuvant chemotherapy (NACT) recipients with available response data. Cox and logistic regression models adjusted for recorded clinicopathological variables. An exploratory cross-sectional analysis of NHANES 2009–2018 was conducted separately. Results In the TNBC cohort, moderate/severe baseline depressive symptoms were associated with differences in T-stage and Ki-67 distributions and a higher frequency of baseline distant metastasis. N-stage distributions did not differ significantly (P = 0.059). Among patients without baseline distant metastasis, adjusted hazard ratios were 1.626 for overall survival (OS; 95% CI: 1.301–2.033; P < 0.001) and 1.439 for disease-free survival (DFS; 95% CI: 1.170–1.770; P < 0.001). The pCR rate was 26.34% in the moderate/severe group versus 36.18% in the normal/mild group (adjusted OR = 0.668; 95% CI: 0.474–0.930; P = 0.018). In NHANES, depressive symptoms were associated with higher odds of a self-reported history of any cancer (OR = 1.41; 95% CI: 1.19–1.67), whereas the breast cancer estimate was not statistically significant (OR = 1.43; 95% CI: 0.97–2.05). Conclusion Moderate/severe baseline depressive symptoms were associated with worse survival and lower pCR in this retrospective TNBC cohort. Reverse causation and unaccounted-for treatment delivery limit interpretation. These findings do not establish a causal effect or the prognostic utility of PHQ-9 beyond established factors. Prospective studies with repeated symptom assessments and detailed treatment records are needed.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: